Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO®

Contributed by: PR Newswire

Tags

Calliditas

More Like This

Calliditas provides patent update

Calliditas Year-end report, January - December 2023

Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®

Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function

Calliditas Therapeutics provides business update ahead of JP Morgan conference

Calliditas Q1 report, January - March 2024

Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress

Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment